Press Release
Schindellegi, Switzerland, November 06th, 2025
Zynnon, a leader in innovative diagnostic solutions, today announced the launch of Bactify™, a next-generation platform designed to detect microbial pathogens directly from positive blood cultures — delivering results in hours instead of days. The company will present the new system at the upcoming MEDICA 2025 Trade Fair in Düsseldorf, Germany, November 17–20, 2025.
Bloodstream infections (BSIs) and sepsis are among the leading causes of mortality worldwide. Microbial detection in blood culture bottles is currently performed either manually or through automated systems (e.g., BacTAlert™, Bactec™), the latter being prohibitively expensive for laboratories in Low- and Middle-Income Countries (LMICs).
Traditional manual, culture-based diagnostic methods can take up to 72 hours, delaying targeted therapy and increasing patient risk. Bactify™ offers a breakthrough alternative — providing rapid, cost-effective detection of bacteria, yeast and fungi through analysis of volatile organic compounds (VOCs) in the bottle headspace. This innovation allows microbiology laboratories, particularly those with limited resources and in LMICs, to semi-automate blood culture analyses, and significantly shorten time-to-positivity, all without the high capital investment required for fully automated systems.
Developed using our proprietary gas microfluidics technology — which replicates the performance of a gas chromatography system at a fraction of the cost — and enhanced by AI-driven pathogen detection, Bactify™ demonstrates promising initial performance in addressing key needs of the target market.
At MEDICA 2025, Zynnon will showcase live demonstrations of Bactify™, highlighting its workflow, technology, and clinical benefits. Visitors will also have the opportunity to meet the team behind the innovation.
📍 Visit Zynnon at MEDICA 2025
Hall 12 | Booth D19-11
Düsseldorf, Germany – November 17–20, 2025
“Bactify™ represents a major step forward in infection diagnostics,” said Khaled Abousaleh, CEO of Zynnon. “We’re excited to bring this innovation to MEDICA and share how it can empower laboratories and healthcare providers to deliver faster, more cost-effective care.” For more information about Bactify™, visit www.zynnon.com or contact Khaled Abousaleh below.
About Zynnon
Zynnon (www.zynnon.com) is a startup transforming infectious pathogen diagnostics, minimizing operations within the laboratory and speeding up the transmission of vital pathogen information to the treating physician in order to optimize treatments and improve patient outcomes. This gaseous biomarker-based solution for the detection of Volatile Organic Compounds (“VOCs”) is used to rapidly and precisely identify bacterial and fungal pathogens to the genus and species level. The VOC-detection and differentiation technology serves as a rapid and efficient alternative or add-on to traditional pathogen identification laboratory methods, substantially shortening the timeline from sample collection to actionable lab results. By streamlining complex procedures into a simple, small, compact, and easy-to-operate sensor-based VOC detector, along with a validated VOC database, the need for specialized laboratory skills for pathogen detection and classification (such as PCR and/or immunoassay-based techniques) is eliminated.
Regulatory Status: WHO Prequalification pending. CE mark and FDA in progress.
Disclaimer: Product not yet available on the market, not for sale.
For media inquiries and additional information, please contact:
Khaled Abousaleh / Zynnon AG
Email: khaled.abousaleh@zynnon.com